Literature DB >> 6335692

Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP.

J A Javitch, S H Snyder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335692     DOI: 10.1016/0014-2999(84)90740-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  35 in total

Review 1.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

2.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

3.  Astrocytes as a primary locus for the conversion MPTP into MPP+.

Authors:  W J Brooks; M F Jarvis; G C Wagner
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  Inward transport of 3H-MPP+ in freshly isolated rat hepatocytes: evidence for interaction with catecholamines.

Authors:  F Martel; M J Martins; I Azevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 5.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

6.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

7.  Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

Authors:  Dhanasekaran Muralikrishnan; Manuchair Ebadi; Holly M Brown-Borg
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

8.  Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss.

Authors:  K Pungor; A Hajnal; K A Kékesi; G Juhász
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

Review 9.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

10.  MPP+ toxicity in rat striatal slices: relationship between non-selective effects and free radical production.

Authors:  S Ambrosio; A Espino; B Cutillas; R Bartrons
Journal:  Neurochem Res       Date:  1996-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.